HEPATOPROTECTIVE EFFECTS OF L-CITRULLINE AGAINST DOXORUBICIN-INDUCED LIVER DAMAGE IN RATS: AN ANALYSIS OF SERUM BIOMARKERS

KELVIN THEANDRO GOTAMA, VIVIAN SOETIKNO*, MELVA LOUISA, WAWAIMULI AROZAL
Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, 10430, Indonesia.
Email: Vivian_09@yahoo.com

Received 20 September 2018, Revised and Accepted 22 February 2019

ABSTRACT

Objective: The antineoplastic agent doxorubicin (DOX) is known for causing liver toxicity. Its metabolism in hepatocytes causes oxidative stress, which, in turn, induces DNA damage, lipid peroxidation, ATP depletion, and apoptosis. L-citrulline (CIT), a commonly found agent in fruits like watermelon, has piqued interest due to its antioxidant properties. In the body, CIT is converted to nitric oxide, which has been shown to mitigate hepatic injury by scavenging free radicals, improving hepatic sinusoidal microcirculation, and inhibiting neutrophilic infiltration. This study aims to investigate CIT ability to prevent DOX-induced hepatotoxicity.

Methods: A total of 20 Wistar rats were randomized to receive either DOX (10 mg/kg BW) or NaCl 0.9%. DOX-intoxicated group was further randomized to either received low-dose CIT (300 mg/kg BW), high-dose CIT (600 mg/kg BW), or aquadest. CIT was given orally for 6 days and DOX through intraperitoneal injection on days 4 and 5. Serum was obtained and hepatotoxicity was assessed with serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyl transferase (GGT). Statistical analysis was done with one-way ANOVA and Tukey’s test.

Results: Serum ALT, AST, and GGT were increased significantly compared to that of normal group. CIT administration in both the doses could decrease the serum levels of ALT and AST significantly compared to that of DOX group. In this study, CIT in both the doses could reduce the serum levels of GGT compared to that of DOX group though not statistically significant.

Conclusions: This study suggests that CIT exerts hepatoprotective effect, as evident by the attenuation of serum biomarkers.

Keywords: Hepatotoxicity, Doxorubicin, L-citrulline.

INTRODUCTION

Doxorubicin (DOX), an anthracycline antibiotic, is a widely used antineoplastic agent with a well-established efficacy against many types of cancer, including breast, lung, gastric, ovarian, and thyroid cancers as well as lymphoma. However, its clinical use is limited due to its toxicity to healthy cells, affecting the heart, liver, brain, and kidneys [1,2].

Hepatotoxicity commonly results from DOX therapy. Overall, 30%–40% of patients receiving DOX injection had elevated serum levels of liver function biomarkers [3,4]. Moreover, DOX use increased the risk of developing liver injury, for example, acute/subacute liver necrosis, toxic hepatitis, and hepatic coma, by 1.29× across all types of cancer [5,6]. Metabolism of DOX in hepatocytes generates an abundance of free radicals, and the resulting oxidative stress induces DNA damage, lipid peroxidation, disturbance of membrane integrity, and ATP depletion, all of which culminate in apoptosis [1,7]. Currently, toxicity prevention only comprises dosage optimization and antioxidant supplementation. Further, no proposed hepatoprotective agent has been approved as a prophylactic drug against DOX-induced liver damage [3,8].

In this regard, L-citrulline (CIT), found in common fruits such as watermelon, has generated interest. A non-protein, non-essential amino acid, CIT was previously thought to be a mere intermediate product of ureagenesis. However, in specific cells of the body, for example, periporal hepatocytes, renal cells, macrophages, and endothelial cells, CIT is recycled into L-arginine (ARG), from which nitric oxide (NO) is synthesized [9,10]. NO is shown to mitigate liver injury by improving hepatic sinusoidal microcirculation, inhibiting neutrophilic infiltration and cytokine production, and scavenging free radicals [11,12]. Remarkably, CIT is reportedly better than ARG in increasing NO bioavailability in the body [13,14]; this may be attributable to CIT-specific metabolism. Unlike ARG, CIT bypasses intestinal first-pass metabolism, thus reaching the systemic circulation in copious amounts [9,10].

An important role of CIT in NO metabolism demonstrates its potential to become a hepatoprotective agent. Only a few studies have evaluated CIT ability to maintain liver function [15,16]. Thus, the present study aimed to evaluate the hepatoprotective effects of CIT administration toward DOX-induced hepatotoxicity in animal models. We believe that this research will help in establishing CIT efficacy in ameliorating organ toxicity caused by DOX and other antineoplastic drugs, thus providing an inexpensive, natural, and widely available prophylactic hepatoprotective agent.

METHODS

Animals
In total, 20 male Wistar rats (250–350 g) were used in this study. The rats were maintained under standardized conditions: Temperature, 23°C; humidity, 55%; and light/dark cycle, 12/12 h. They were allowed to acclimatize 1 week before the initiation of the experiment. All rats had access to food and water ad libitum. This study was approved by the ethics committee in Indonesia (ethical clearance #0928/UN2.F1/ETIK/2018).

Experimental design
This was an experimental laboratory study. The rats were randomly divided into four groups (n=4 rats/group) and received treatment throughout the 6-day experiment accordingly (Table 1). Determination of dosage was based on a study by Hayward and Hydock (for DOX) and...
Yi et al. [17,18]. At the end of the experiment, the rats were euthanized with an intraperitoneal injection of ketamine (80 mg/kg BW) and xylazine (8 mg/kg BW). Supracardiac puncture was performed to euthanize the rats and collect blood samples.

The blood samples were stored in a plain tube without an anticoagulant, allowed to clot at room temperature (±28°C), and centrifuged at 3000 rpm for 10 min. The separated supernatant, i.e. serum was collected in microtubes and stored at −80°C until needed.

Assessment of hepatotoxicity
Hepatotoxicity was assessed on the basis of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyl transferase (GGT) serum levels. Assays were performed using commercial diagnostic kits from DiaSys®, following the provided protocol. Serum biomarker activity is expressed in units/liter.

Statistical analysis
Data were analyzed using IBM SPSS Statistics version 22 and expressed as mean ± standard deviation. The Shapiro–Wilk test was used to assess data normality and Levene test to assess data variance. One-way ANOVA test and Tukey’s multiple comparison test were used to determine differences between the treatment groups. Kruskal–Wallis test and Mann–Whitney U-test were performed in case of heterogeneity of variance. p<0.05 was considered to be statistically significant.

RESULTS
Effects of CIT administration on serum ALT activity of DOX-intoxicated rats
DOX intoxication resulted in ×2.61 elevation of mean serum ALT activity, which was significantly higher compared with that in the normal group (p<0.05; Table 2, Fig. 1a). Concomitant administration of CIT with DOX resulted in significantly lower serum ALT activity compared with DOX alone (p<0.05), and this was observed for both the doses of CIT. High-dose CIT administration decreased ALT activity significantly more than low-dose CIT (p<0.05), suggesting a dose-dependent effect.

Effects of CIT administration on serum AST activity of DOX-intoxicated rats
DOX treatment caused a ×2.26 increase in serum AST levels, which was significantly higher than that in the normal group (p<0.05). Low-dose CIT administration with DOX only caused an insignificant reduction in AST levels in comparison with DOX administration alone (p>0.05). However, high-dose CIT administration with DOX resulted in significantly lower serum AST activity compared with administration of DOX alone (p<0.05). Further, there was a significant difference (p<0.05) between the low- and high-dose groups; hence, a dose-dependent effect of CIT may also exist (Table 2 and Fig. 1b).

Effects of CIT administration on serum GGT activity of DOX-intoxicated rats
DOX treatment significantly elevated the levels of GGT in serum, with a mean activity that was ×7.93 higher than that observed in the normal group (p<0.05). Concomitant CIT administration, regardless of whether it was low or high dose, resulted in an insignificant decrease of mean serum GGT activity when compared with administration of DOX alone (p<0.05). While high-dose CIT administration lowered GGT level more than its low-dose counterpart, no statistically significant difference existed between the two (p>0.05; Table 2 and Fig. 1c).

DISCUSSION
In the present study, DOX intoxication of rats significantly elevated all serum biomarkers of liver function; this finding was expected and is consistent with those of previous studies. Dewanjee et al. reported that DOX-treated rats had increased serum AST, ALT, total cholesterol, and triglyceride levels accompanied with enhanced lipid peroxidation and increased apoptotic protein expression [19]. Damodor et al. reported that breast cancer patients undergoing DOX therapy had significantly increased AST, ALT, direct bilirubin, and total bilirubin levels from pre-chemotherapy to the fourth cycle of chemotherapy [3].

The underlying mechanism for DOX-induced elevation of serum biomarkers is well documented. An abundance of reactive oxygen species (ROS) is produced when DOX is metabolized in hepatocytes, and the resulting oxidative stress causes DNA damage, lipid peroxidation, and disruption of membrane integrity. Further, ROS attacks inorganic phosphates, thus depleting hepatocytes of ATP and consequently triggering apoptosis. These events permit the escape of cytosolic enzymes, for example, ALT, AST, and GGT, from hepatocytes into the circulation, thereby increasing their serum levels [1,2,7,20].

Elevations of serum ALT and AST were significantly attenuated with concomitant administration of CIT, an effect better achieved with the high-dose administration (600 mg/kg BW). This finding is in agreement with those of other studies evaluating CIT hepatoprotective ability. Moussa et al. reported on rats with modeled ischemia/reperfusion injury and found that CIT treatment significantly reduced elevations of ALT and AST (p<0.05), along with lactate dehydrogenase, arginine, and intrahepatic myeloperoxidase activity [15]. In addition, Legatheesan et al. identified a significant decrease of plasma ALT levels due to CIT in rats with fructose-induced liver steatosis. They also reported a decreased, although statistically insignificant, elevation of AST level (p>0.05) [16].

Table 1: Treatment groups and their respective regimen

| Group I (normal) | Days 1–6: Aquadest through gavage, ×1/day |
|------------------|------------------------------------------|
| Group II (DOX)   | *Days 4–5: As above+IP injection of 0.9% NaCl |
| Group III (CIT low dose) | Days 1–6: Oral low-dose CIT (300 mg/kg BW), ×1/day |
| Group IV (CIT high dose) | Days 1–6: Oral high-dose CIT (600 mg/kg BW), ×1/day |

CIT: L-citrulline, DOX: Doxorubicin, IP: Intraperitoneal

Table 2: Level of serum biomarkers of liver function across treatment groups¹

| Serum levels | I Normal | II DOX | III low-dose CIT | IV high-dose CIT | p-value |
|--------------|----------|--------|------------------|------------------|---------|
| Serum ALT(U/L) | 23.96±6.96* | 62.67±11.96* | 4.199±5.89* | 35.02±3.14* | <0.01 |
| Serum AST(U/L) | 39.68±5.22* | 89.82±6.97* | 83.81±9.87* | 60.54±19.47* | <0.01 |
| Serum GGT(U/L) | 1.09±0.45* | 8.65±6.39* | 4.31±4.27* | 2.21±0.70* | 0.026 |

ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, CIT: L-citrulline, DOX: Doxorubicin, GGT: Gamma-glutamyltransferase, U/L: Units/liter. *Data are presented as mean±standard deviation. In a row, data labeled with different letters differ significantly (p<0.05). ¹Heterogeneity of variance: Kruskal–Wallis test, followed by Mann–Whitney U-test, was performed.
highly indicative of liver damage as ALT is found almost exclusively in hepatocytes [21]. Thus, its activity is considered a specific and sensitive indicator of hepatocellular damage. In addition, ALT is considered superior to AST in predicting hepatic injury among pre-clinical species such as rats and dogs [22,23]. AST, although found in hepatocytes, is also present in the heart, skeletal muscle, and kidneys, and thus, AST elevation is less specific for liver injury [21,23]. ALT elevation is usually more marked than AST elevation when the cause of elevation is hepatic due to longer half-life of ALT and higher proportion of AST bound to the mitochondria. Conversely, extrahepatic origin should be suspected when AST is more elevated than ALT [21-23]. The present study found greater ALT than AST elevation (×2.61 vs. ×2.26), confirming that DOX causes hepatocellular damage.

Furthermore, CIT capacity to significantly lower DOX-induced AST and ALT elevations in the present study demonstrates its hepatoprotective ability, which may be attributable to CIT antioxidative properties. Several studies have shown that CIT, as the precursor of ARG, potently increases NO levels in the body [13,14]. While we did not measure the NO levels following CIT administration in this study, we believe that CIT boosted NO production because NO is shown to scavenge superoxides and other free radicals, thereby mitigating oxidative stress caused by DOX metabolism in hepatocytes. Moreover, NO induces sinusoidal vasodilation, inhibits platelet aggregation, reduces neutrophilic infiltration, and inhibits cytokine release, all of which contribute to the mitigation of liver injury [11,12].

Introduction of CIT to DOX-intoxicated rats lowered the elevations of serum GGT, although insignificantly (p<0.05). Moussaoui et al. did not utilize GGT as part of their liver integrity assessment. However, they found that CIT significantly reduced elevations of all serum biomarkers, in which the present study failed to demonstrate [15]. Jegatheesan et al. used alkaline phosphatase (ALP), a marker of hepatobiliary injury similar to GGT; however, they also found that CIT only caused insignificant attenuation of ALP elevation [16].

Concentrated in the epithelial lining of bile ducts, GGT is an indicator of hepatobiliary injury. The findings of GGT support those of ALP, which is a more sensitive but less specific marker. GGT elevation also helps to confirm that elevations of AST and ALT are of hepatic origin [21,23]. Thus, decreased levels of GGT following the introduction of CIT as seen in this study also demonstrate CIT hepatoprotective ability.

CONCLUSIONS

The results of this study suggest that CIT applies a hepatoprotective effect, as evidenced by the attenuation of elevated serum biomarkers induced by DOX. The precise mechanism behind this must be further evaluated, especially in regard to the bioavailability of NO following the introduction of CIT, as previous studies have demonstrated NO ability in maintaining liver integrity. Nevertheless, using CIT, commonly found from food constituent, compensates organ toxicities induced by chemotherapeutic agents such as DOX may be a feasible clinical strategy.

ACKNOWLEDGMENT

This research was conducted under the supervision of Wawaimuli Arozal and Melva Louisa from the Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Indonesia. Dr. Vivian Soetikno (PhD, Sp.FK) as the research supervisor guided the execution of this research and analysis of data. The authors of this paper would like to express their gratitude to Gregorius Bhashara Wilanendra and Wenny Trias Ramadanty for their expert technical assistance. This research was granted by Directorate Research and Community Service, University of Indonesia, Jakarta, Indonesia.

CONFLICTS OF INTEREST

The authors declare no competing interests.
REFERENCES
1. Tacar O, Srimornsak P, Dass CR. Doxorubicin: An update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol 2013;65:157-70.
2. Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, et al. Doxorubicin pathways: Pharmacodynamics and adverse effects. Pharmacogenet Genomics 2011;21:440-6.
3. Damodar G, Smitha T, Gopinath S, Vijayakummar S, Rao YA. An evaluation of hepatotoxicity in breast cancer patients receiving injection doxorubicin. Ann Med Health Sci Res 2014;4:74-9.
4. Yang XL, Fan CH, Zhu HS. Photo-induced cytotoxicity of malonic acid [C(60)]fullerene derivatives and its mechanism. Toxicol In Vitro 2002;16:41-6.
5. Bhandari NR, Shewale AR, Kathe NJ, Shah AB, Painter JT. Association between the use of doxorubicin and risk of developing hepatotoxicity among cancer patients. Value Health 2016;19:A134.
6. El-Sayyad HI, Ismail MF, Shalaby FM, El-Magd RF, Gaur RL, Fernando A, et al. Histopathological effects of cisplatin, doxorubicin and 5-fluorouracil (5-FU) on the liver of male albino rats. Int J Biol Sci 2009;5:466-73.
7. Bengaied D, Ribeiro A, Anri M, Scherman D, Arnaud P. Reduction of hepatotoxicity induced by doxorubicin. J Integr Oncol 2017;6:193.
8. Grigorian A, O’Brien CB. Hepatotoxicity secondary to chemotherapy. J Clin Transl Hepatol 2014;2:95-102.
9. Bahri S, Zerrouk N, Assel C, Moinard C, Crenn P, Curis E, et al. Citrulline: From metabolism to therapeutic use. Nutrition 2013;29:479-84.
10. Papadis C, Osofska S, Cynober L, Forbes A. Citrulline in health and disease. Review on human studies. Clin Nutr 2018;37:1823-8.
11. Rajapakse NW, Mattson DL. Role of L-arginine in nitric oxide production in health and hypertension. Clin Exp Pharmacol Physiol 2009;36:249-55.
12. Taha MO, Simões MJ, Haddad MA, Capelato RC, Budny N, Matsumoto AH, et al. L-arginine supplementation protects against hepatic ischemia-reperfusion lesions in rabbits. Transplant Proc 2009;41:816-9.
13. Suzuki T, Morita M, Kobayashi Y, Kamimura A. Oral L-citrulline supplementation enhances cycling time trial performance in healthy trained men: Double-blind randomized placebo-controlled 2-way crossover study. J Int Soc Sports Nutr 2016;13:1-8.
14. Morita M, Hayashi T, Ochiai M, Maeda M, Yamaguchi T, Ika K, et al. Oral supplementation with a combination of L-citrulline and L-arginine rapidly increases plasma L-arginine concentration and enhances NO bioavailability. Biochem Biophys Res Comm 2014;454:53-7.
15. Moussaoui F, Binimbi A, Cottart CH, Arnal N, Vamy M, Nivet-Antoine V, et al. Hepatoprotective effect of citrulline against ischemia-reperfusion injury in rat. J Hepatol 2009;50:S68.
16. Jegatheesan P, Beutheu S, Ventura G, Nabret E, Sarfati G, Bergheim I, et al. Citrulline and nonessential amino acids prevent fructose-induced nonalcoholic fatty liver disease in rats. J Nutr 2015;145:2273-9.
17. Hayward R, Hydock DS. Doxorubicin cardiotoxicity in the rat: An in vivo characterization. J Am Assoc Lab Anim Sci 2007;46:20-32.
18. Yi L, Lingshan G, Cui Y, Xiaoxing Y, Junnian Z. A preliminary study on protective effect of L-citrulline against ischemia-reperfusion induced gastric mucosal lesions in rat. Indian J Pharmaco 2012;44:31-5.
19. Dewanjee S, Joardar S, Bhattacharjee N, Dua TK, Das S, Kalita J, et al. Edible leaf extract of ipomoea aquatica forssk. (Convolvulaceae) attenuates doxorubicin-induced liver injury via inhibiting oxidative impairment, MAPK activation and intrinsic pathway of apoptosis. Food Chem Toxicol 2017;105:322-36.
20. Mohajeri M, Sahelkar A. Protective effects of curcumin against doxorubicin-induced toxicity and resistance: A review. Crit Rev Oncol Hematol 2018;122:30-51.
21. Aulbach AD, Amuzie CJ. Biomarkers in Nonclinical Drug Development. In: A Comprehensive Guide to Toxicology in Nonclinical Drug Development. Elsevier; 2017. p. 447-71. Available from: http://www.linkinghub.elsevier.com/retrieve/pii/B9780128036204000177. [Last accessed on 2018 Jun 26].
22. Boone L, Meyer D, Cusick P, Emulad T, Bolliger AP, Everss N, et al. Selection and interpretation of clinical pathology indicators of hepatic injury in preclinical studies. Vet Clin Pathol 2005;34:182-8.
23. York MJ. Clinical Pathology. In: A Comprehensive Guide to Toxicology in Nonclinical Drug Development. Elsevier; 2017 p. 325-74. Available from: http://www.linkinghub.elsevier.com/retrieve/pii/B978012803620400014I. [Last accessed on 2018 Jun 26].